Renatus Inc., a pharmaceutical company focused on developing cholesterol metabolism modulators, today announced the registration of a U.S. patent No. 11931376 entitled “METHODS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE.”

Dysregulated renal cholesterol metabolism can contribute to the progression of chronic kidney disease (CKD). Treatment with RN-005 in preclinical models of CKD has shown to effectively reverse cholesterol and triglycerides accumulation and promote normalization of cholesterol metabolism pathways in the kidney. Modulation of cholesterol metabolism in the kidney by RN-005 exerts significant renoprotective effects, lowering serum creatinine and BUN levels and albuminuria, which are key indicators of kidney function and damage, respectively.

Heegon Kim, CEO of Renatus, commented: “Cholesterol metabolism plays crucial roles in the development of chronic kidney disease, making it a new promising therapeutic target. To date, however, there is no drug that can promote cholesterol metabolism and efflux in the kidney. The patent reinforces the value of our cholesterol modulator RN-005 as a potential treatment for chronic kidney disease.”

To keep updated, please follow:

LinkedIn Page: https://www.linkedin.com/company/renatustx/ 

About RENATUS

Renatus is a pharma company thriving to develop next generation cyclodextrins to provide safe treatment options for patients living with cholesterol-associated diseases. Renatus seeks to provide critical impact in developing translational cyclodextrin therapies and fulfill its vision to protect the world from various cholesterol-associate diseases. For more information, please visit www.renatustx.com